Lancet 2005; 366: 1849 1861. 94. Ting RD, Keech AC, Drury PL et al. Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment: the FIELD Study. Diabetes Care 2012; 35: 218 225. 95. Davis TM, Ting R, Best JD et al. Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. Diabetologia 2011; 54: 280 290. 96. Ginsberg HN, Elam MB, Lovato LC et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010; 362: 1563 1574. 97. Zhao YY, Weir MA, Manno M et al. New fibrate use and acute renal outcomes in elderly adults a population-based study. Ann Intern Med 2012; 156: 560 569. 98. Chen HH, Lin LH. Recurrent pancreatitis secondary to type V hyper- lipidemia: report of one case. Acta Paediatr Taiwan 2000; 41: 276 278. 99. Spratt P, Esmore D, Keogh A et al. Comparison of three immunosuppressive protocols in cardiac transplantation. Transplant Proc 1989; 21: 2481 2483. 100. Chicaud P, Demange J, Drouin P et al. [Action of fenofibrate in hypercholesterolemic children. 18-month follow-up]. Presse Med 1984; 13: 417 419. 101. Steinmetz J, Morin C, Panek E et al. Biological variations in hyperlipidemic children and adolescents treated with fenofibrate. Clin Chim Acta 1981; 112: 43 53. 102. Wheeler KA, West RJ, Lloyd JK et al. Double blind trial of bezafibrate in familial hypercholesterolaemia. Arch Dis Child 1985; 60: 34 37. 103. Cerkauskiene R, Kaminskas A, Kaltenis P et al. Influence of omega-3 fatty acids on lipid metabolism in children with steroid sensitive nephrotic syndrome]. Medicina 2003; 39(Suppl 1): 82-87. 104. Chongviriyaphan N, Tapaneya-Olarn C, Suthutvoravut U et al. 